
BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target
BioMarin Pharmaceutical (BMRN) Analyst Ratings
Bulls say
BioMarin Pharmaceutical is supported by a resilient rare-disease franchise, with mature enzyme therapies generating $2.1B in 2025 and growing at high single-digits, while VOXZOGO is expected to deliver $1B in sales generation in 2026 despite competitor entry. The company also has meaningful near-term operating leverage, as 3Q26 revenue reached $1.025B, operating cash generation was about $188M, and acquired assets such as GALAFOLD and POMBILITI + OPFOLDA added $152M and $49M in their first full quarter under BioMarin. Its outlook is further strengthened by an expanding pipeline, including BMN 333’s 2027 growth update, BMN 440’s 2027 data, and BMN 820’s 2028 readout, which could extend growth beyond the base business.
Bears say
BioMarin Pharmaceutical is viewed cautiously because its growth engine, VOXZOGO, is already showing softening momentum, with 3Q26 revenue of $245M, ~85% U.S. retention, and a lowered 2026 sales guide of $975M-$1.025B amid shipment timing issues and a daily-injection burden. Competitive pressure is intensifying as BridgeBio’s oral infigratinib has a February 4, 2027 FDA action date before VOXZOGO’s May 30 HCH decision, while management plans to stop U.S. switching disclosure in 4Q26, reducing visibility into erosion. Although the base business and royalties from YUVIWEL help offset some weakness, the 2026 non-GAAP EPS guide was cut to $2.80-$3.10 from $4.90-$5.10, with most of the decline tied to Alesta and BMN 450 deal costs and a relatively light pipeline offering limited near-term upside.
This aggregate rating is based on analysts' research of BioMarin Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
BioMarin Pharmaceutical (BMRN) Analyst Forecast & Price Prediction
Start investing in BioMarin Pharmaceutical (BMRN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About BioMarin Pharmaceutical (BMRN) Forecast
BioMarin Pharmaceutical (BMRN) Analyst Forecast & Price Prediction
Start investing in BioMarin Pharmaceutical (BMRN)
Order type
Buy in
Order amount
Est. shares
0 shares